Navigation Links
FDA Accepts IND for Arno Therapeutics' Pan-DAC / Akt Inhibitor, AR-42
Date:3/17/2009

p>

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings, as well as our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management, are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
4. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
5. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
6. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
7. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
8. FDA Accepts Immucors Response to Warning Letter
9. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
10. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
11. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... WORMS, GERMANY – May 26, ... GRA) announces that its manufacturing facility in Worms, ... from EXCiPACT™, an independent organization that certifies manufacturers, ... , All three Grace facilities that produce its ... gels have now received GMP certification, following the ...
(Date:5/26/2015)... May 26, 2015   Intrexon Corporation (NYSE: ... Gregory Frost , Ph.D., Senior Vice President and Head ... Global Healthcare Conference on Wednesday, June 3 rd , at ... New York City . About Intrexon ... Powering the Bioindustrial Revolution with Better DNA ™ to ...
(Date:5/26/2015)... , May 26, 2015   PDI , ... today announced that Oakwood Healthcare in ... the winning entry in Delivering the ... who display excellence in building collaborative relationships between ... in healthcare facilities.  Oakwood Healthcare,s ...
(Date:5/26/2015)... , May 26, 2015 Mr. Kevin ... family, thanks President Barack Obama and President ... the time of loss of Dr. Rongxiang Xu , ... and a leader ahead of his time, Dr. Xu,s commitment ... community leave a legacy that will not be forgotten. As ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, Beyond A Legend 2
... Board of Directors of the Pittsburgh Life Sciences Greenhouse ... formation and business growth services to the region,s life ... of Peter M. DeComo as the new Chairman of ... will replace Dr. D. Lansing Taylor who is stepping ...
... hair-like blood vessels in the back of our eyes, researchers ... those that bring blood to the heart respond to air ... otherwise healthy people exposed to high levels of air pollution ... of heart disease. Previous studies linked pollution to heart ...
... In 2008, experiments at The Fu Foundation School of ... graphene, a single layer of graphite only one atom ... raised a question for Chris Marianetti, Assistant Professor in ... how and why does graphene break? ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board 2Photos of tiny blood vessels in the eye link air pollution to heart disease 2Columbia engineering team discovers graphene's weakness 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... The founder of a public database that helps doctors ... decisions is the 2009 recipient of the March of ... field of genetic sciences. Roberta "Bonnie" Pagon, MD, ... of Medicine in Seattle, developed the Web site genetests.org ...
... have observed the initiation of a mass gathering and subsequent ... case, fish. The work, conducted using a novel imaging ... that vast oceanic fish shoals inhabit," the team writes in ... also confirms theories about the behavior of large groups of ...
... unveiled the evolutionary origin of the different chromosomal ... comprehensive comparison of the Agrobacterium sequence information with ... general model for how second chromosomes are formed ... Rhizobiaceae family, which also includes the benign, nitrogen-fixing ...
Cached Biology News:Roberta A. Pagon receives lifetime award in genetics from March of Dimes 2Team IDs genesis of mass migrations 2Team IDs genesis of mass migrations 3Evolutionary origin of bacterial chromosomes revealed 2
... Ready-to-use liquid controls for monitoring Aldolase ... & abnormal) with targeted manufacturing values ... 20 ± 3 IU/L. 30-day ... at 2-8 C. Level 1: 3 ...
Request Info...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Recombinant Mouse Noggin...
Biology Products: